SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Frostman who wrote (9076)6/4/1998 8:20:00 AM
From: Anaxagoras  Read Replies (1) of 23519
 
<<Nearly 1,000 men and their partners participated in the three-month home-treatment phase of the study. After in-clinic testing to find a suitable dose, 64.9 percent of the men treated with MUSE (alprostadil) reported sexual intercourse compared with 18.6 percent of the patients on placebo. >>

Thanks for the reminder, Frostman.

Note the endpoint, folks.

It's kinda important.

Part of the goal in the whole darn intimacy thang.

Note that it's not the same as the endpoint reported in the "disappointing" studies.

Similarly, you'll recall that the endpoint of hanging 1 kilogram weights from the end of a stiffy wasn't achieved with wonderful results by using MUSE either.

Such a shame. ;-)

Anaxagoras
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News